A Phase 1 study of RC88 in advanced solid tumors

Study Description

A study to test the safety and tolerability of an investigational drug (RC88) in patients with advanced solid tumors

Study Details

Registry ID:

NCT05508334

Conditions:

Advanced Solid Tumours

Phase:

Phase 1,Phase 2

Target Enrollment:

41 participants

Start Date:

January 30, 2023

Age Range:

18–70 years

Healthy Volunteers:

No

Study Locations (4 sites)

• Remegen
  Beijing, BeijingChina, China
• Remgenen
  Beijing, BeijingChina, China
• Remegen
  Beijing, Beijing MunicipalityChina, China
• Remgenen
  Beijing, Beijing MunicipalityChina, China

Interested in Participating?

Check your eligibility and learn more about this study on TrialScreen.

View full study details and check eligibility →